Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03662126




Registration number
NCT03662126
Ethics application status
Date submitted
5/09/2018
Date registered
7/09/2018
Date last updated
28/04/2023

Titles & IDs
Public title
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Scientific title
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
Secondary ID [1] 0 0
KRT-232-101
Universal Trial Number (UTN)
Trial acronym
BOREAS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Myelofibrosis (PMF) 0 0
Post-Polycythemia Vera MF (Post-PV-MF) 0 0
Post-Essential Thrombocythemia MF (Post-ET-MF) 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - KRT-232
Treatment: Drugs - Best Available Therapy (BAT)

Experimental: Part A Cohort 1 - KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

Experimental: Part A Cohort 2 - KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

Experimental: Part A Cohort 3 - KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)

Experimental: Part A Cohort 4b - KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)

Experimental: Part B Arm 1 KRT-232 - KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)

Active Comparator: Part B Arm 2 Best Available Therapy - Best available therapy at the discretion of the investigator, on a 28-day cycle.


Treatment: Drugs: KRT-232
KRT-232, administered by mouth

Treatment: Drugs: Best Available Therapy (BAT)
Best available therapy options include:
hydroxyurea
chemotherapy or
supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
(Part A Only) Spleen Volume Reduction (SVR)
Timepoint [1] 0 0
24 weeks
Primary outcome [2] 0 0
(Part B Only) Spleen Volume Reduction (SVR)
Timepoint [2] 0 0
24 Weeks
Secondary outcome [1] 0 0
(Part A only) Improvement in Total Symptom Score (TSS)
Timepoint [1] 0 0
48 weeks
Secondary outcome [2] 0 0
(Part B only) Improvement of Total Symptom Score (TSS)
Timepoint [2] 0 0
24 Weeks
Secondary outcome [3] 0 0
(Part B only) Overall Survival (OS)
Timepoint [3] 0 0
48 months
Secondary outcome [4] 0 0
(Part B only) Progression free survival (PFS)
Timepoint [4] 0 0
48 months
Secondary outcome [5] 0 0
(Part B Only) Overall Spleen Volume Reduction (SVR)
Timepoint [5] 0 0
48 months
Secondary outcome [6] 0 0
(Part B Only) Spleen Response Duration
Timepoint [6] 0 0
48 months
Secondary outcome [7] 0 0
(Part B Only) Rate of conversion from RBC transfusion dependent to independent
Timepoint [7] 0 0
24 weeks

Eligibility
Key inclusion criteria
- Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)

- High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System
(DIPSS)

- Failure of prior treatment with JAK inhibitor

- ECOG = 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior splenectomy

- Splenic irradiation within 3 months prior to randomization

- History of major hemorrhage or intracranial hemorrhage within 6 months prior to
randomization

- History of stroke, reversible ischemic neurological defect or transient ischemic
attack within 6 months prior to randomization

- Prior MDM2 inhibitor therapy or p53-directed therapy

- Prior allogeneic stem-cell transplant or plans for allogeneic stem cell transplant

- History of major organ transplant

- Grade 2 or higher QTc prolongation (> 480 milliseconds per NCI-CTCAE criteria, version
5.0)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Crossover
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/01/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2025
Actual
Sample size
Target
385
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [2] 0 0
Fiona Stanley Hosital - Murdoch
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [5] 0 0
South Eastern Private Hospital - Noble Park
Recruitment hospital [6] 0 0
Icon Cancer Center - South Brisbane
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
6150 - Murdoch
Recruitment postcode(s) [3] 0 0
- Adelaide
Recruitment postcode(s) [4] 0 0
- Melbourne
Recruitment postcode(s) [5] 0 0
3174 - Noble Park
Recruitment postcode(s) [6] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
South Dakota
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Argentina
State/province [14] 0 0
Santa Fe
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Caba
Country [17] 0 0
Argentina
State/province [17] 0 0
Córdoba
Country [18] 0 0
Brazil
State/province [18] 0 0
Ceara
Country [19] 0 0
Brazil
State/province [19] 0 0
Parana
Country [20] 0 0
Brazil
State/province [20] 0 0
São Paulo
Country [21] 0 0
Brazil
State/province [21] 0 0
Goiânia
Country [22] 0 0
Brazil
State/province [22] 0 0
Jau
Country [23] 0 0
Brazil
State/province [23] 0 0
Porto Alegre
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Pleven
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Plovdiv
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Canada
State/province [28] 0 0
Ontario
Country [29] 0 0
Croatia
State/province [29] 0 0
Sibenik
Country [30] 0 0
Croatia
State/province [30] 0 0
Zagreb
Country [31] 0 0
Czechia
State/province [31] 0 0
Králová
Country [32] 0 0
Czechia
State/province [32] 0 0
Nové Mesto
Country [33] 0 0
Czechia
State/province [33] 0 0
Olomouc
Country [34] 0 0
France
State/province [34] 0 0
Amiens
Country [35] 0 0
France
State/province [35] 0 0
Angers
Country [36] 0 0
France
State/province [36] 0 0
Bayonne
Country [37] 0 0
France
State/province [37] 0 0
Brest Cedex
Country [38] 0 0
France
State/province [38] 0 0
Caen
Country [39] 0 0
France
State/province [39] 0 0
Le Mans
Country [40] 0 0
France
State/province [40] 0 0
Nîmes
Country [41] 0 0
France
State/province [41] 0 0
Paris
Country [42] 0 0
France
State/province [42] 0 0
Poitiers
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
France
State/province [44] 0 0
Villejuif
Country [45] 0 0
Germany
State/province [45] 0 0
Bayern
Country [46] 0 0
Germany
State/province [46] 0 0
Nordrhein-Westfalen
Country [47] 0 0
Germany
State/province [47] 0 0
Sachsen-Anhalt
Country [48] 0 0
Germany
State/province [48] 0 0
Sachsen
Country [49] 0 0
Germany
State/province [49] 0 0
Thuringen
Country [50] 0 0
Germany
State/province [50] 0 0
Berlin
Country [51] 0 0
Germany
State/province [51] 0 0
Hamburg
Country [52] 0 0
Germany
State/province [52] 0 0
Mainz
Country [53] 0 0
Germany
State/province [53] 0 0
Mutlangen
Country [54] 0 0
Germany
State/province [54] 0 0
Saarbrücken
Country [55] 0 0
Greece
State/province [55] 0 0
Ioannina
Country [56] 0 0
Greece
State/province [56] 0 0
Patras
Country [57] 0 0
Greece
State/province [57] 0 0
Thessaloníki
Country [58] 0 0
Hong Kong
State/province [58] 0 0
Hong Kong
Country [59] 0 0
Hong Kong
State/province [59] 0 0
Shatin
Country [60] 0 0
Hungary
State/province [60] 0 0
Somogy
Country [61] 0 0
Hungary
State/province [61] 0 0
Szabolcs-Szatmar-Bereg
Country [62] 0 0
Hungary
State/province [62] 0 0
Vas
Country [63] 0 0
Hungary
State/province [63] 0 0
Budapest
Country [64] 0 0
Hungary
State/province [64] 0 0
Debrecen
Country [65] 0 0
Hungary
State/province [65] 0 0
Szeged
Country [66] 0 0
Israel
State/province [66] 0 0
Afula
Country [67] 0 0
Israel
State/province [67] 0 0
Ashdod
Country [68] 0 0
Israel
State/province [68] 0 0
Haifa
Country [69] 0 0
Israel
State/province [69] 0 0
Jerusalem
Country [70] 0 0
Israel
State/province [70] 0 0
Kfar Saba
Country [71] 0 0
Israel
State/province [71] 0 0
Nahariya
Country [72] 0 0
Israel
State/province [72] 0 0
Petah Tikva
Country [73] 0 0
Israel
State/province [73] 0 0
Tel Aviv
Country [74] 0 0
Israel
State/province [74] 0 0
Zerifin
Country [75] 0 0
Italy
State/province [75] 0 0
Lombardia
Country [76] 0 0
Italy
State/province [76] 0 0
Alessandria
Country [77] 0 0
Italy
State/province [77] 0 0
Ancona
Country [78] 0 0
Italy
State/province [78] 0 0
Bologna
Country [79] 0 0
Italy
State/province [79] 0 0
Brescia
Country [80] 0 0
Italy
State/province [80] 0 0
Catania
Country [81] 0 0
Italy
State/province [81] 0 0
Firenze
Country [82] 0 0
Italy
State/province [82] 0 0
Meldola
Country [83] 0 0
Italy
State/province [83] 0 0
Milano
Country [84] 0 0
Italy
State/province [84] 0 0
Novara
Country [85] 0 0
Italy
State/province [85] 0 0
Pesaro
Country [86] 0 0
Italy
State/province [86] 0 0
Reggio Emilia
Country [87] 0 0
Italy
State/province [87] 0 0
Roma
Country [88] 0 0
Italy
State/province [88] 0 0
Torino
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Busan
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Daegu
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Seongnam-si
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
Seoul
Country [93] 0 0
Lithuania
State/province [93] 0 0
Kaunas
Country [94] 0 0
Mexico
State/province [94] 0 0
Nuevo Leon
Country [95] 0 0
Mexico
State/province [95] 0 0
Monterrey
Country [96] 0 0
Mexico
State/province [96] 0 0
Oaxaca
Country [97] 0 0
Mexico
State/province [97] 0 0
Veracruz
Country [98] 0 0
Philippines
State/province [98] 0 0
Cebu City
Country [99] 0 0
Philippines
State/province [99] 0 0
Manila
Country [100] 0 0
Poland
State/province [100] 0 0
Dolnoslaskie
Country [101] 0 0
Poland
State/province [101] 0 0
Podkarpackie
Country [102] 0 0
Poland
State/province [102] 0 0
Slaskie
Country [103] 0 0
Poland
State/province [103] 0 0
Bydgoszcz
Country [104] 0 0
Poland
State/province [104] 0 0
Lublin
Country [105] 0 0
Poland
State/province [105] 0 0
Olsztyn
Country [106] 0 0
Poland
State/province [106] 0 0
Opole
Country [107] 0 0
Poland
State/province [107] 0 0
Poznan
Country [108] 0 0
Poland
State/province [108] 0 0
Slupsk
Country [109] 0 0
Portugal
State/province [109] 0 0
Aveiro
Country [110] 0 0
Portugal
State/province [110] 0 0
Braga
Country [111] 0 0
Portugal
State/province [111] 0 0
Coimbra
Country [112] 0 0
Portugal
State/province [112] 0 0
Lisboa
Country [113] 0 0
Portugal
State/province [113] 0 0
Lisbon
Country [114] 0 0
Romania
State/province [114] 0 0
Brasov
Country [115] 0 0
Romania
State/province [115] 0 0
Bucharest
Country [116] 0 0
Romania
State/province [116] 0 0
Bucuresti
Country [117] 0 0
Romania
State/province [117] 0 0
Cluj-Napoca
Country [118] 0 0
Romania
State/province [118] 0 0
Craiova
Country [119] 0 0
Romania
State/province [119] 0 0
Iasi
Country [120] 0 0
Romania
State/province [120] 0 0
Timisoara
Country [121] 0 0
Romania
State/province [121] 0 0
Târgu-Mures
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Omsk
Country [123] 0 0
Russian Federation
State/province [123] 0 0
St Petersburg
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Syktyvkar
Country [125] 0 0
Spain
State/province [125] 0 0
Barcelona
Country [126] 0 0
Spain
State/province [126] 0 0
Las Palmas
Country [127] 0 0
Spain
State/province [127] 0 0
Madrid
Country [128] 0 0
Spain
State/province [128] 0 0
Cáceres
Country [129] 0 0
Spain
State/province [129] 0 0
Málaga
Country [130] 0 0
Spain
State/province [130] 0 0
Palma de Mallorca
Country [131] 0 0
Spain
State/province [131] 0 0
Pamplona
Country [132] 0 0
Spain
State/province [132] 0 0
Salamanca
Country [133] 0 0
Spain
State/province [133] 0 0
Valencia
Country [134] 0 0
Spain
State/province [134] 0 0
Zaragoza
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taipei
Country [136] 0 0
Taiwan
State/province [136] 0 0
Chiayi City
Country [137] 0 0
Taiwan
State/province [137] 0 0
Kaohsiung
Country [138] 0 0
Taiwan
State/province [138] 0 0
Taichung
Country [139] 0 0
Thailand
State/province [139] 0 0
Bangkok
Country [140] 0 0
Thailand
State/province [140] 0 0
Khlong Luang
Country [141] 0 0
Thailand
State/province [141] 0 0
Khon Kaen
Country [142] 0 0
Thailand
State/province [142] 0 0
Songkhla
Country [143] 0 0
Turkey
State/province [143] 0 0
Adapazari
Country [144] 0 0
Turkey
State/province [144] 0 0
Ankara
Country [145] 0 0
Turkey
State/province [145] 0 0
Denizli
Country [146] 0 0
Turkey
State/province [146] 0 0
Gaziantep
Country [147] 0 0
Turkey
State/province [147] 0 0
Malatya
Country [148] 0 0
Turkey
State/province [148] 0 0
Mersin
Country [149] 0 0
Turkey
State/province [149] 0 0
Samsun
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Birmingham
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Glasgow
Country [152] 0 0
United Kingdom
State/province [152] 0 0
London
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Kartos Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK
inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.

This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose
and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in
the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT
(Arm 2). The BAT administered will be determined by the treating physician, with the option
to "cross-over" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any
time.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03662126
Trial related presentations / publications
Al-Ali, H.K.; Delgado, R.G.; Lange, A.; Pluta, A.; McLornan, D.; Vachhani, P.; Damaj, G.L.; Jost, P.J.; Rejto, L.; Hus, M.; et al. KRT-232, A First-In-Class, Murine Double Minute 2 Inhibitor, for Myelofibrosis Relapsed or Refractory to Janus-Associated Kinase Inhibitor Treatment. Eha. Libr. 2020, 295035, S215
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
John Mei
Address 0 0
Country 0 0
Phone 0 0
650-542-0136
Fax 0 0
Email 0 0
jmei@kartosthera.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03662126